203 related articles for article (PubMed ID: 32533097)
1. The BLIMP1-EZH2 nexus in a non-Hodgkin lymphoma.
Anderson KJ; Ósvaldsdóttir ÁB; Atzinger B; Traustadóttir GÁ; Jensen KN; Lárusdóttir AE; Bergthórsson JT; Hardardóttir I; Magnúsdóttir E
Oncogene; 2020 Jul; 39(28):5138-5151. PubMed ID: 32533097
[TBL] [Abstract][Full Text] [Related]
2. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
[TBL] [Abstract][Full Text] [Related]
3. Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis.
Caganova M; Carrisi C; Varano G; Mainoldi F; Zanardi F; Germain PL; George L; Alberghini F; Ferrarini L; Talukder AK; Ponzoni M; Testa G; Nojima T; Doglioni C; Kitamura D; Toellner KM; Su IH; Casola S
J Clin Invest; 2013 Dec; 123(12):5009-22. PubMed ID: 24200695
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals.
Gutiérrez NC; Ocio EM; de Las Rivas J; Maiso P; Delgado M; Fermiñán E; Arcos MJ; Sánchez ML; Hernández JM; San Miguel JF
Leukemia; 2007 Mar; 21(3):541-9. PubMed ID: 17252022
[TBL] [Abstract][Full Text] [Related]
5. Updates in prognostication and treatment of Waldenström's macroglobulinemia.
Advani P; Paulus A; Ailawadhi S
Hematol Oncol Stem Cell Ther; 2019 Dec; 12(4):179-188. PubMed ID: 31158330
[TBL] [Abstract][Full Text] [Related]
6. IL-1beta expression in IgM monoclonal gammopathy and its relationship to multiple myeloma.
Donovan KA; Lacy MQ; Gertz MA; Lust JA
Leukemia; 2002 Mar; 16(3):382-5. PubMed ID: 11896542
[TBL] [Abstract][Full Text] [Related]
7. [Lymphoplasmacytic lymphoma with Waldenström's macroglobulinemia: a clinicopathological and immunophenotypic study of 40 Chinese patients].
Liang DN; Li GD; Dai L; Huang J; Wang WY; Feng WH; Li FY; Liao DY
Zhonghua Bing Li Xue Za Zhi; 2009 Nov; 38(11):728-32. PubMed ID: 20079010
[TBL] [Abstract][Full Text] [Related]
8. Epigenomics in Waldenstrom's macroglobulinaemia.
Sacco A; Fenotti A; Bazzana S; Imberti L; Rossi G; Patterson CJ; Treon SP; Ghobrial IM; Roccaro AM
Best Pract Res Clin Haematol; 2016 Jun; 29(2):156-160. PubMed ID: 27825461
[TBL] [Abstract][Full Text] [Related]
9. Nuclear protein dysregulation in lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia.
Roberts MJ; Chadburn A; Ma S; Hyjek E; Peterson LC
Am J Clin Pathol; 2013 Feb; 139(2):210-9. PubMed ID: 23355206
[TBL] [Abstract][Full Text] [Related]
10. The 3D Genome: EZH2 Comes into the Fold.
Brien GL; Bracken AP
Trends Mol Med; 2019 May; 25(5):362-365. PubMed ID: 30885427
[TBL] [Abstract][Full Text] [Related]
11. Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.
Roccaro AM; Leleu X; Sacco A; Moreau AS; Hatjiharissi E; Jia X; Xu L; Ciccarelli B; Patterson CJ; Ngo HT; Russo D; Vacca A; Dammacco F; Anderson KC; Ghobrial IM; Treon SP
Clin Cancer Res; 2008 Mar; 14(6):1849-58. PubMed ID: 18347188
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Owen RG; Treon SP; Al-Katib A; Fonseca R; Greipp PR; McMaster ML; Morra E; Pangalis GA; San Miguel JF; Branagan AR; Dimopoulos MA
Semin Oncol; 2003 Apr; 30(2):110-5. PubMed ID: 12720118
[TBL] [Abstract][Full Text] [Related]
13. Lymphoplasmacytic lymphoma and Waldenström macroglobulinaemia: clinicopathological features and differential diagnosis.
Wang W; Lin P
Pathology; 2020 Jan; 52(1):6-14. PubMed ID: 31767130
[TBL] [Abstract][Full Text] [Related]
14. Key role of microRNAs in Waldenström's macroglobulinemia pathogenesis.
Sacco A; Maiso P; Azab A; Azab F; Zhang Y; Liu Y; Ngo HT; Morgan B; Quang P; Issa G; Ghobrial IM; Roccaro AM
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):109-11. PubMed ID: 21454206
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.
Agarwal P; Alzrigat M; Párraga AA; Enroth S; Singh U; Ungerstedt J; Österborg A; Brown PJ; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2016 Feb; 7(6):6809-23. PubMed ID: 26755663
[TBL] [Abstract][Full Text] [Related]
16. Aspirin exerts anti-tumor effect through inhibiting Blimp1 and activating ATF4/CHOP pathway in multiple myeloma.
Liu H; Xiong C; Liu J; Sun T; Ren Z; Li Y; Geng J; Li X
Biomed Pharmacother; 2020 May; 125():110005. PubMed ID: 32070879
[TBL] [Abstract][Full Text] [Related]
17. IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia.
Hodge LS; Ziesmer SC; Yang ZZ; Secreto FJ; Gertz MA; Novak AJ; Ansell SM
Blood; 2012 Nov; 120(18):3774-82. PubMed ID: 22976953
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS.
Garcia-Reyero J; Martinez Magunacelaya N; Gonzalez de Villambrosia S; Gomez Mediavilla A; Urquieta Lam M; Insunza A; Tonda R; Beltran S; Gut M; Gonzalez A; Montes-Moreno S
J Clin Pathol; 2020 Sep; 73(9):571-577. PubMed ID: 31980558
[TBL] [Abstract][Full Text] [Related]
19. Abnormalities in lymphocyte profile and specificity repertoire of patients with Waldenstrom's macroglobulinemia, multiple myeloma, and IgM monoclonal gammopathy of undetermined significance.
Pilarski LM; Andrews EJ; Serra HM; Ledbetter JA; Ruether BA; Mant MJ
Am J Hematol; 1989 Feb; 30(2):53-60. PubMed ID: 2536515
[TBL] [Abstract][Full Text] [Related]
20. Differential diagnosis of Waldenstrom's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders.
Pangalis GA; Kyrtsonis MC; Kontopidou FN; Vassilakopoulos TP; Siakantaris MP; Dimopoulou MN; Kittas C; Angelopoulou MK
Semin Oncol; 2003 Apr; 30(2):201-5. PubMed ID: 12720136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
